News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SWOG Selects Sequenta’s LymphoSIGHT™ Platform for Use in 180-Patient Mantle Cell Lymphoma Clinical Trial


8/6/2012 9:28:56 AM

SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. announced today that SWOG has selected Sequenta’s LymphoSIGHT™ platform for the measurement of Minimal Residual Disease (MRD) in a clinical trial.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES